Abstract
In today's Lancet, the DIRECT investigators report two pivotal papers from the DIRECT (DIabetic REtinopathy Candesartan Trials) study, which randomised 5231 patients with type 1 or type 2 diabetes into daily placebo or 32 mg candesartan, an angiotensin II receptor blocker).1,2 The study recruited from 309 worldwide sites, and followed up patients for 4 years. The investigators report on prevention and progression of diabetic retinopathy in type 1 diabetes (respectively: DIRECT-Prevent 1, n=1421; DIRECT-Protect 1, n=1905),1 and on progression and regression of diabetic retinopathy in type 2 diabetes (DIRECT-Protect 2, n=1905).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
